Skip to main content

Trial Milestone: MA36 (OlympiA)

Trial Milestone: MA36 (OlympiA)

OlympiA: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

It was recently announced that the OlympiA trial IDMC review has concluded that the study has met the pre-specified criteria for superiority for the primary endpoint of iDFS at the planned interim analysis and that no safety signals of concern were noted. They recommended the data be unblinded and primary analysis conducted without delay. The OlympiA trial Steering Committee has accepted the recommendation. The planned primary analysis of the data at last database lock will now be performed and the results will be submitted for consideration for oral presentation at the next international cancer congress.

This has been an outstanding and truly global academic and industry partnership working on behalf of women with high recurrence risk, genetic breast cancer. It has been an OlympiAn effort to get to this point, especially during the current Covid-19 pandemic. I would like to take this opportunity on behalf of my Study Co-Chairs, the academic Study Partners and the Study Sponsors to thank you, your staff and your patients for your support and dedication in reaching this important milestone and for your ongoing commitment to the study.

Professor Andrew Tutt MB ChB PhD FMedSci, OlympiA Study Chair